Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,585 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NMO-IgG detected in CSF in seronegative neuromyelitis optica.
Klawiter EC, Alvarez E 3rd, Xu J, Paciorkowski AR, Zhu L, Parks BJ, Cross AH, Naismith RT. Klawiter EC, et al. Among authors: alvarez e 3rd. Neurology. 2009 Mar 24;72(12):1101-3. doi: 10.1212/01.wnl.0000345066.57745.50. Neurology. 2009. PMID: 19307546 Free PMC article. No abstract available.
Detection of cortical lesions in multiple sclerosis: A new imaging approach.
Patel KR, Luo J, Alvarez E, Piccio L, Schmidt RE, Yablonskiy DA, Cross AH. Patel KR, et al. Among authors: alvarez e. Mult Scler J Exp Transl Clin. 2015 Sep 24;1:2055217315606465. doi: 10.1177/2055217315606465. eCollection 2015 Jan-Dec. Mult Scler J Exp Transl Clin. 2015. PMID: 28607704 Free PMC article.
Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B; MS-MRIUS investigators. Zivadinov R, et al. Among authors: alvarez e. J Neuroimaging. 2018 Jul;28(4):399-405. doi: 10.1111/jon.12518. Epub 2018 May 11. J Neuroimaging. 2018. PMID: 29749661
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators. Fox RJ, et al. Among authors: alvarez e. N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583. N Engl J Med. 2018. PMID: 30157388 Free PMC article. Clinical Trial.
Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.
Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B; MS-MRIUS Study Group. Zivadinov R, et al. Among authors: alvarez e. Mult Scler Relat Disord. 2019 Jan;27:65-73. doi: 10.1016/j.msard.2018.09.037. Epub 2018 Oct 3. Mult Scler Relat Disord. 2019. PMID: 30342416
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
1,585 results